December 2, 2025
Dr. David Granville – Ph.D., FAHA
Dr. David Granville
Ph.D., FAHA
Dr. Granville is a Professor and Associate Dean, Research, VCHRI, UBC, and Executive Director, VCHRI. His early research at QLT Inc. supported the FDA approval of Visudyne® as the first treatment for age-related macular degeneration, the leading cause of blindness in the elderly. At Scripps he identified a novel therapeutic approach for reducing ischemia and reperfusion injury that led to the formation of Radical Therapeutix. Since returning to UBC, his lab has filed 32 patents that have been licensed to industry. He is also a co-Founder/CSO of viDA Therapeutics. He is currently focused on identifying therapeutic targets that contribute to aging and chronic diseases.